Novo bets big on diabetes meds

Share this article:

Novo Nordisk is investing $3.65 billion in needle-free diabetes treatments. Reuters reports that the drug maker is looking to develop pills that can replace injected insulins, and tells the news service it has dedicated 500 employees to developing six candidates.

The company projects that it could have the new medication market-ready in 10 years.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Imbruvica lassoes CLL indication

The FDA slapped a Breakthrough Therapy label on the CLL indication pursuit in February.

FDA asks social media "how'm I doin?"

The FDA's Center for Drug Evaluation and Research's Office of Communications wants a system that will help assess its messaging reach across the interwebs and its many forums.

Reckitt Benckiser wants out of pharma

The company plans to spin off its pharmaceutical unit.